Futura Medical PLC (AIM:FUM, OTC:FAMDF) posted record results with £14 million in revenue and a £1.3 million profit as Eroxon sales grew. CEO James Barder said the product is now sold in over 15 countries, with more launches and new treatments on the way.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has partnered with the NHS Cancer Vaccine Launchpad to speed up recruitment for its melanoma vaccine trial. CEO Phillip L’Huillier called it a major endorsement, with more trial data due in 2025.
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) is teaming up with US-based Heureka Labs to use AI in its gene therapy research. CEO Dr Eric Leire said AI will help make sense of complex data and boost pipeline progress.
Ilika PLC (AIM:IKA, OTCQX:ILIKF) says its Goliath battery tech is outperforming expectations thanks to work with the UK Battery Industrialisation Centre. CEO Graeme Purdy said improved yields and stronger battery performance keep it on track for prototype releases this year.
Solvonis Therapeutics PLC (LSE:SVNS) fully pivoted to biotech in its 2024 financial year, raising £1.8 million and planning to acquire mental health specialist Awakn Life Sciences. CEO Anthony Tennyson said the deal unlocks major growth, with clinical trials and FDA filings top of the agenda for 2025.
